In Focus
Autoinjectors have long been associated with adrenaline pens used to treat severe allergic reactions. In recent years, pre-filled injection pens have also become widely recognised through GLP-1 medicines for diabetes and obesity.
But beyond these high-profile medicines, a broader trend is emerging, with a growing number of pharmaceutical companies exploring whether treatments in other therapeutic areas can be administered subcutaneously rather than through intravenous infusions. For some, autoinjectors could also allow treatment to move from hospital to patients' homes, reducing hospital visits and easing the burden on healthcare services.
BREAKING